Dr Tycel Phillips, is a lymphoma specialist with a research and clinical focus on non-hodgkin lymphoma. Dr Phillips completed his hematology-oncology fellowship at University Hospitals/Case Western University. While at Case Western, Dr Phillips began to focus on the development of clinical trials utilizing novel agents in lymphoma. He has continued his focus on clinical research upon his appointment at the University of Michigan and in addition has been the site primary investigator on numerous clinical trials in multiple subtypes of lymphoma. Dr Phillips’s research interests include evaluation of resistance mechanisms in mantle cell lymphoma (MCL), non-cytotoxic chemotherapeutic treatment in frontline MCL, and other novel combinations in relapsed/refractory lymphoma. Dr Phillips is involved in professional societies including the American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH).
Dr. Tycel Phillips discusses new agents in diffuse large B-cell lymphoma and follicular lymphoma
Dr. Tycel J. Phillips discusses the Role of PI3K inhibitors in Non-Hodgkin’s Lymphoma
A review paper ‘Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs’ authored by LYMPHOMA CONNECT members